[1] Huikuri H V, Castellanos A, Myerburg R J. Sudden death due to cardiac arrhythmias[J]. New England Journal of Medicine, 2001, 345(20): 1473-1482.
[2] Habecker B A, Anderson M E, Birren S J, et al. Molecular and cellular neurocardiology: development, and cellular and molecular adaptations to heart disease[J]. The Journal of physiology, 2016, 594(14): 3853-3875.
[3] Kimura K, Ieda M, Fukuda K. Development, maturation, and transdifferentiation of cardiac sympathetic nerves[J]. Circulation research, 2012, 110(2): 325-336.
[4] Rana I, Stebbing M, Kompa A, et al. Microglia activation in the hypothalamic PVN following myocardial infarction[J]. Brain research, 2010, 1326: 96-104.
[5] Pinto B B, Ritter C, Michels M, et al. Characterization of Brain–Heart Interactions in a Rodent Model of Sepsis[J]. Molecular neurobiology, 2017, 54(5): 3745-3752.
[6] Lampert R, Jain D, Burg M M, et al. Destabilizing effects of mental stress on ventricular arrhythmias in patients with implantable cardioverter-defibrillators[J]. Circulation, 2000, 101(2): 158-164.
[7] Napadow V, Dhond R, Conti G, et al. Brain correlates of autonomic modulation: combining heart rate variability with fMRI[J]. Neuroimage, 2008, 42(1): 169-177.
[8] Kang Y M, Zhang A Q, Zhao X F, et al. Paraventricular nucleus corticotrophin releasing hormone contributes to sympathoexcitation via interaction with neurotransmitters in heart failure[J]. Basic research in cardiology, 2011, 106(3): 473-483.
[9] Kang Y M, He R L, Yang L M, et al. Brain tumour necrosis factor-α modulates neurotransmitters in hypothalamic paraventricular nucleus in heart failure[J]. Cardiovascular research, 2009, 83(4): 737-746.
[10] Qi J, Zhao X F, Yu X J, et al. Targeting interleukin-1 beta to suppress sympathoexcitation in hypothalamic paraventricular nucleus in Dahl salt-sensitive hypertensive rats[J]. Cardiovascular toxicology, 2016, 16(3): 298-306.
[11] Sallam M Y, El-Gowilly S M, Abdel-Galil A G A, et al. Central GABA A receptors are involved in inflammatory and cardiovascular consequences of endotoxemia in conscious rats[J]. Naunyn-Schmiedeberg's archives of pharmacology, 2016, 389(3): 279-288.
[12] Suzuki S, Tanaka K, Suzuki N. Ambivalent aspects of interleukin-6 in cerebral ischemia: inflammatory versus neurotrophic aspects[J]. Journal of Cerebral Blood Flow & Metabolism, 2009, 29(3): 464-479.
[13] Ali C, Nicole O, Docagne F, et al. Ischemia-induced interleukin-6 as a potential endogenous neuroprotective cytokine against NMDA receptor-mediated excitoxicity in the brain[J]. Journal of Cerebral Blood Flow & Metabolism, 2000, 20(6): 956-966.
[14] Scheller J, Chalaris A, Schmidt-Arras D, et al. The pro-and anti-inflammatory properties of the cytokine interleukin-6[J]. Biochimica et BiophysicaActa (BBA)-Molecular Cell Research, 2011, 1813(5): 878-888.
[15] Mihara M, Hashizume M, Yoshida H, et al. IL-6/IL-6 receptor system and its role in physiological and pathological conditions[J]. Clinical science, 2012, 122(4): 143-159.
[16] Wu J, Guo W, Lin S Z, et al. Gp130-mediated STAT3 activation by S-propargyl-cysteine, an endogenous hydrogen sulfide initiator, prevents doxorubicin-induced cardiotoxicity[J]. Cell death & disease, 2016, 7(8): e2339.
[17] Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer[C]//Seminars in immunology. Academic Press, 2014, 26(1): 54-74.
[18] Fontes J A, Rose N R, Čiháková D. The varying faces of IL-6: From cardiac protection to cardiac failure[J]. Cytokine, 2015, 74(1): 62-68.
[19] Garbers C, Aparicio-Siegmund S, Rose-John S. The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition[J]. Current opinion in immunology, 2015, 34: 75-82.
[20] Chen X, Wei J, Li C, et al. Blocking interleukin-6 signaling inhibits cell viability/proliferation, glycolysis, and colony forming activity of human medulloblastoma cells[J]. International journal of oncology, 2018, 52(2): 571-578.
[21] Todd L, Squires N, Suarez L, et al. Jak/Stat signaling regulates the proliferation and neurogenic potential of Müller glia-derived progenitor cells in the avian retina[J]. Scientific reports, 2016, 6: 35703.
[22] Oshima T, Cao X, Grande F, et al. Combination effects of SC144 and cytotoxic anticancer agents[J]. Anti-cancer drugs, 2009, 20(5): 312-320.
[23] Xu S, Grande F, Garofalo A, et al. Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer[J]. Molecular cancer therapeutics, 2013.
[24] Gao H L, Yu X J, Liu K L, et al. PVN blockade of p44/42 MAPK pathway attenuates salt-induced hypertension through modulating neurotransmitters and attenuating oxidative stress[J]. Scientific Reports, 2017, 7: 43038.
[25] Sung P H, Lee F Y, Lin L C, et al. Melatonin attenuated brain death tissue extract-induced cardiac damage by suppressing DAMP signaling[J]. Oncotarget, 2018, 9(3): 3531.
[26] Su Q, Huo C J, Li H B, et al. Renin-angiotensin system acting on reactive oxygen species in paraventricular nucleus induces sympathetic activation via AT1R/PKCγ/Rac1 pathway in salt-induced hypertension[J]. Scientific reports, 2017, 7: 43107.
[27] Yin J, Wang Y, Hu H, et al. P2X7 receptor inhibition attenuated sympathetic nerve sprouting after myocardial infarction via the NLRP3/IL‐1β pathway[J]. Journal of cellular and molecular medicine, 2017, 21(11): 2695-2710.
[28] Yin J, Hu H, Li X, et al. Inhibition of Notch signaling pathway attenuates sympathetic hyperinnervation together with the augmentation of M2 macrophages in rats post-myocardial infarction[J]. American Journal of Physiology-Cell Physiology, 2015, 310(1): C41-C53.
[29] Yanagisawa M, Yu R K. The expression and functions of glycoconjugates in neural stem cells[J]. Glycobiology, 2007, 17(7): 57R-74R.
[30] Martin D S, Haywood J R. Sympathetic nervous system activation by glutamate injections into the paraventricular nucleus[J]. Brain research, 1992, 577(2): 261-267.
[31] Olivas A, Gardner R T, Wang L, et al. Myocardial infarction causes transient cholinergic transdifferentiation of cardiac sympathetic nerves via gp130[J]. Journal of Neuroscience, 2016, 36(2): 479-488.
[32] Hajiasgharzadeh K, Mirnajafi-Zadeh J, Mani A R. Interleukin-6 impairs chronotropic responsiveness to cholinergic stimulation and decreases heart rate variability in mice[J]. European journal of pharmacology, 2011, 673(1-3): 70-77.
[33] Habecker B A, Sachs H H, Rohrer H, et al. The dependence on gp130 cytokines of axotomy induced neuropeptide expression in adult sympathetic neurons[J]. Developmental neurobiology, 2009, 69(6): 392-400.
[34] Li W, Knowlton D, Woodward W R, et al. Regulation of noradrenergic function by inflammatory cytokines and depolarization[J]. Journal of neurochemistry, 2003, 86(3): 774-783.
[35] Parrish D C, Alston E N, Rohrer H, et al. Absence of gp130 in dopamine β-hydroxylase-expressing neurons leads to autonomic imbalance and increased reperfusion arrhythmias[J]. American Journal of Physiology-Heart and Circulatory Physiology, 2009, 297(3): H960-H967.